IQVIA Holdings (IQV) News
Market Cap: $31.74B
Avg Volume: 1.43M
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation.
zacks.com
Read More
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.
zacks.com
Read More
Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation
UPPER NYACK, N.Y.--(BUSINESS WIRE)--When pharmacists can't give adult vaccinations, millions of people go without them.
businesswire.com
Read More
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Read More
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questio.
businesswire.com
Read More
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead.
businesswire.com
Read More
IQVIA Releases 2024 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr.
businesswire.com
Read More
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
zacks.com
Read More
IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way
IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years.
seekingalpha.com
Read More
IQVIA (IQV) International Revenue Performance Explored
Explore how IQVIA's (IQV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
zacks.com
Read More
IQVIA Earnings & Revenues Surpass Estimates in Q4, Increase Y/Y
Growth in the Research and Development, and Technology and Analytics segments aids IQV's top line in the fourth quarter of 2024.
zacks.com
Read More
IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Kerri Joseph – Senior Vice President, Investor Relations and Treasury Ari Bousbib – Chairman and Chief Executive Officer Ron Bruehlman – Executive Vice President and Chief Financial Officer Conference Call Participants Shlomo Rosenbaum – Stifel Elizabeth Anderson – Evercore ISI Ann Hynes – Mizuho David Windley – Jefferies Charles Rhyee – TD Cowen Jack Meehan – Nephron Research Michael Ryskin – Bank of America Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2024 Earnings Conference Call.
seekingalpha.com
Read More
IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions
On Thursday, IQVIA Holdings Inc IQV reported a fourth adjusted EPS of $3.12, up from $2.84, beating the consensus of $3.11.
benzinga.com
Read More
Here's What Key Metrics Tell Us About IQVIA (IQV) Q4 Earnings
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Read More
IQVIA Holdings (IQV) Beats Q4 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $3.10 per share. This compares to earnings of $2.84 per share a year ago.
zacks.com
Read More
IQVIA beats quarterly results estimates on analytics services demand
Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.
reuters.com
Read More
IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024. "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari Bousbib, chairman and CEO of IQVIA. "R&DS revenue was on target and bookings exceeded o.
businesswire.com
Read More
IQVIA Gears Up to Report Q4 Earnings: What's in Store for the Stock?
IQV's top line in the fourth quarter of 2024 is expected to have benefited from the rising use of GenAI to provide crucial insights.
zacks.com
Read More
IQVIA named to the Fortune® World's Most Admired Companies™ list, ranked No. 1 in its sector for fourth consecutive year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World's Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on fou.
businesswire.com
Read More
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Read More
IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Read More
Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zacks.com
Read More
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Read More
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
Read More
Will IQVIA (IQV) Beat Estimates Again in Its Next Earnings Report?
IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Read More
IQVIA Benefits From Global IT Infrastructure Amid Low Liquidity
The IQV stock gains from its $330-billion addressable market and an enormous trove of data, which is its distinguishing asset.
zacks.com
Read More
IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains?
IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
Read More
Iqvia initiated with an Overweight at Stephens
Stephens initiated coverage of Iqvia with an Overweight rating and $250 price target. The firm says the company has "fulfilled the promise" of combining a leading contract research organization and the largest life science data repository to connect intelligence that advances healthcare. The analyst views the company's Q3 reset, as well as the recent outline of "reasonably conservative" fiscal 2025 and long-term growth frameworks, as creating an attractive setup "for a well-run industry bellwether."
https://thefly.com
Read More
IQVIA Holdings: Share Price Disconnected From Growth Outlook
IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance with $3.9B revenue, 14.1% EPS growth, and a $31.1B backlog, reinforcing long-term growth potential. Analysts project slower CRO growth, but IQVIA's leadership, consistent earnings, and long-term revenue estimates of $28.45B by 2033 support a bullish outlook.
seekingalpha.com
Read More
Why You Should Retain IQVIA Holdings Stock in Your Portfolio Now
IQV is known for its innovative use of technology and data analytics.
zacks.com
Read More
Interpreting IQVIA (IQV) International Revenue Trends
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
zacks.com
Read More
IQVIA (IQV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Read More
IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q3 2024 Results Conference Call October 31, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations & Treasury Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Eric Sherbet - Executive Vice President and General Counsel Mike Fedock - Senior Vice President, Financial Planning and Analysis Gustavo Peroni - Senior Director, Investor Relations Conference Call Participants Ann Hynes - Mizuho Shlomo Rosenbaum - Stifel Anne Samuel - JP Morgan Luke Sergott - Barclays Bank Justin Bowers - Deutsche Bank David Windley - Jefferies Elizabeth Anderson - Evercore ISI Michael Cherny – Leerink Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Third Quarter 2024 Earnings Conference Call.
seekingalpha.com
Read More
IQVIA Earnings & Revenues Surpass Estimates in Q3, Increase Y/Y
Strength in the Research and Development, and Technology and Analytics segments drives IQV's top line in the third quarter of 2024.
zacks.com
Read More
IQVIA lowers annual revenue forecast amid trial delays
Contract research firm IQVIA lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges.
reuters.com
Read More
IQVIA Holdings (IQV) Q3 Earnings and Revenues Beat Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.49 per share a year ago.
zacks.com
Read More
IQVIA Gears Up to Report Q3 Earnings: Here's What You Should Know
IQV's TAS and RD&S revenues are anticipated to have increased, while CSMS revenues are likely to have dipped in the third quarter of 2024.
zacks.com
Read More
Seeking Clues to IQVIA (IQV) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for IQVIA (IQV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
zacks.com
Read More
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Here's Why You Should Retain IQVIA Holdings Shares Now
While IQV benefits from its market leadership, data-driven innovation and global expansion, it must navigate pricing pressure.
zacks.com
Read More
IQV Gains From Clinical Development Capabilities Amid Low Liquidity
IQVIA's vast database, health-care-specific IT infrastructure and analytics-driven developments enable it to grow in the $300-billion market.
zacks.com
Read More
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Read More
Contract Research Giant IQVIA's Data Assets Are Biggest Differentiator, Provides Best Exposure To AI And Data Opportunities: Analyst
RBC Capital Markets initiated coverage on IQVIA Holdings Inc. IQV, noting the company's biggest differentiator is its data assets. The analyst says IQVIA is the largest global contract research organization.
benzinga.com
Read More
Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative
PHILADELPHIA , Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative.
prnewswire.com
Read More
IQVIA (IQV) Up 3.4% Since Last Earnings Report: Can It Continue?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
Reiterating Buy On IQVIA After Q2 Earnings
IQVIA Holdings Inc. stock is up following Q2 earnings, following business upsides across its portfolio. Q2 earnings showed strong performance in TAS and R&DS divisions, with a record backlog and increased guidance for FY'24. Implied valuations are corroborated at a $260/share price objective, with potential further technical upside to $283/share if momentum sustains.
seekingalpha.com
Read More
Here's Why You Should Retain IQVIA (IQV) Stock for Now
IQVIA (IQV) rides high on robust segmental performance, boosting the company's top line. However, elevated operating expenses and weak liquidity are a major concern.
zacks.com
Read More
Understanding IQVIA (IQV) Reliance on International Revenue
Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
zacks.com
Read More
IQV vs. WAT: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Waters (WAT). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Read More
These Analysts Boost Their Forecasts On IQVIA After Better-Than-Expected Earnings
IQVIA Holdings Inc IQV posted better-than-expected second-quarter earnings on Monday.
benzinga.com
Read More
Compared to Estimates, IQVIA (IQV) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Read More
IQVIA Stock Pops After It Beats Q2 Earnings Estimates
IQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.
investopedia.com
Read More
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q2
IQVIA's (IQV) second-quarter 2024 earnings and revenues increase year over year.
zacks.com
Read More
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings
IQVIA Holdings Inc IQV reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.
benzinga.com
Read More
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.64 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to earnings of $2.43 per share a year ago.
zacks.com
Read More
IQVIA raises annual profit forecast on improving demand for analytics services
Contract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.
reuters.com
Read More
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.
zacks.com
Read More
Clinical Development Expertise Aids IQVIA (IQV), Costs High
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.
zacks.com
Read More
IQVIA (IQV) Announces Launch of Trial Technology Platform
IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.
zacks.com
Read More
IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production.
seekingalpha.com
Read More
Here's Why You Should Hold on to IQVIA (IQV) Stock for Now
IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.
zacks.com
Read More
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q1
IQVIA's (IQV) rise in segmental revenues results in y/y top-line growth in first-quarter 2024.
zacks.com
Read More
IQVIA trims full-year revenue forecast on stronger dollar
Contract research firm IQVIA Holdings lowered its annual revenue forecast on Thursday due to a stronger dollar and reported a quarter-over-quarter fall in a closely-watched metric, sending shares down nearly 4%.
reuters.com
Read More
IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.45 per share a year ago.
zacks.com
Read More
Analysts Are Pounding the Table on These 3 Stocks: April 2024
Sometimes a company's debut or the release of a new product can stir analysts into a frenzy. Other times, careful consideration of long-term trends and performance can drive improved public opinion of a company's prospects.
investorplace.com
Read More
IQVIA (IQV) to Report Q1 Earnings: What's in the Offing?
IQVIA Holdings' (IQV) first-quarter 2024 revenues are likely to have benefited from growth in the Technology and Analytics, and Research and Development segments.
zacks.com
Read More
Countdown to IQVIA (IQV) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for IQVIA (IQV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
zacks.com
Read More
Reasons to Retain IQVIA (IQV) Stock in Your Portfolio Now
IQVIA (IQV) is benefitting from its robust capabilities and expansive strategy amid low liquidity and foreign currency exchange rate fluctuation risks.
zacks.com
Read More
IQVIA (IQV) Appreciates 24% in a Year: Here's What to Know
IQVIA's (IQV) combined offerings of research and development and commercial services are helping it to develop trusted relationships.
zacks.com
Read More
IQVIA (IQV) Up 5.3% Since Last Earnings Report: Can It Continue?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
IQVIA (IQV) Gains From Global IT Framework, Liquidity Low
IQVIA's (IQV) revenue growth is primarily driven by global IT infrastructure and market size amid increasing operating expenses and low liquidity.
zacks.com
Read More
IQVIA Holdings, Inc. (IQV) Q4 2023 Earnings Call Transcript
IQVIA Holdings, Inc. (IQV) Q4 2023 Earnings Call Transcript
seekingalpha.com
Read More
IQVIA Holdings (IQV) Q4 Earnings & Revenues Beat Estimates
IQVIA Holdings' (IQV) revenues increase year over year in fourth-quarter 2023.
zacks.com
Read More
Compared to Estimates, IQVIA (IQV) Q4 Earnings: A Look at Key Metrics
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
IQVIA Holdings (IQV) Surpasses Q4 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.82 per share. This compares to earnings of $2.78 per share a year ago.
zacks.com
Read More
IQVIA quarterly results beat estimates on strong demand for research services
IQVIA Holdings beat Wall Street estimates for fourth-quarter sales and profit on Wednesday, on the back of strong demand for its drug research and development services.
reuters.com
Read More
IQVIA (IQV) to Report Q4 Earnings: What's in the Offing?
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
zacks.com
Read More
Stay Ahead of the Game With IQVIA (IQV) Q4 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zacks.com
Read More
IQV or IDXX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Read More
4 GARP Stocks to Scoop up for Maximum Returns
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NRG, DRI, ALSN and IQV are some stocks that hold promise.
zacks.com
Read More
IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024
INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the p.
businesswire.com
Read More
Here's Why You Should Invest in IQVIA Holdings (IQV) Now
IQVIA's (IQV) combined offerings of research and development and commercial services help it to develop trusted relationships.
zacks.com
Read More
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
The great advances and improvements in the treatment of diseases and the effectiveness of these medicines are undoubtedly due to technological progress and how biotech companies take advantage of it for their growth and development. Without the work of these companies, we would still be using very old and ineffective medicines.
investorplace.com
Read More
IQVIA (IQV) Climbs 17% in 3 Months: Here's What to Know
IQVIA (IQV) benefits from revenue growth and disciplined cost management.
zacks.com
Read More
3 Charts For Investors to Watch Tuesday: IQVIA Holdings, BGC Group, WGMI ETF
Here's our daily look at three charts linked to recent news-driven price moves, with key technical levels to watch.
investopedia.com
Read More
Seven tech stocks that can broaden your exposure beyond the “Magnificent Seven”
During the bull market of 2023, the “Magnificent Seven” stocks have dominated financial media coverage, and rightly so. There is no question that this group of companies has been performing very well in their core businesses and analysts expect the good times to continue.
marketwatch.com
Read More
IQVIA (IQV) Stock Gains 8% in a Month: Here's What to Know
IQVIA (IQV) aims at market expansion through innovation and service improvements.
zacks.com
Read More
Why Is IQVIA (IQV) Up 12.4% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year
INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category. Nominations for the PM360 Trailblazer Awards, which recognize outstanding achievement and innovation in healthcare marketing, are judged by their Editorial Advisory Board of industry experts.
businesswire.com
Read More
IQVIA CFO Ron Bruehlman to Speak at Evercore HealthCONx Conference on November 29, 2023
INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is.
businesswire.com
Read More
IQVIA Announces Upsizing of its Allocation of New Term B Loans
INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Borrower”), allocated a new term B loan due 2031 of approximately $1,500 million (the “New Term Loan B”), which was upsized due to lender demand. The proceeds from the New Term Loan B, together with the proceeds from the Borrower's offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), are expe.
businesswire.com
Read More
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes
INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), priced an offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), which was upsized due to strong demand. Substantially concurrently with the closing of this offering, the Borrower intends to amend its senior secured credit facilities (the “Credit Agreement Amendment”) to.
businesswire.com
Read More
IQVIA Announces Offering of Senior Secured Notes
INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), intends to raise $500,000,000 through an offering of senior secured notes due 2029 (the “Notes”). Substantially concurrently with the closing of this offering, the Borrower intends to amend its senior secured credit facilities (the “Credit Agreement Amendment”) to provide for a new term B loan of approximately $1,250 mi.
businesswire.com
Read More
IQVIA: I Would Stay Away Until Debt Issues Are Resolved
IQVIA is a global provider of contract research services and data analytics for the healthcare industry. The company helps clients drive healthcare forward by providing insights and solutions to improve. The Net Debt/EBITDA ratio is 4.6x, moreover, 55% of its debt is at a floating rate, which is very worrying in an environment with high rates. Although the company doesn't seem particularly expensive at its current valuation, I would demand a greater margin of safety until debt concerns are resolved.
seekingalpha.com
Read More